Authors
Loading...
Randomized trial evaluated fingolimod's antibacterial effects against carbapenem-resistant Acinetobacter baumannii, suggesting a new treatment avenue.
Jin et al. (2026) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: